This is somewhat true. The efficacy was proven in phase 2. The issue here seems to be more the design of the trial and possibly the masks used. Additionally, for public speaking, people tend to get less nervous the more they do it. I nearly passed out the first time I had to present in front of 300 people 15 yrs ago. I now look forward to presenting in front of large groups.
Lastly, the real prize is not the public speaking efficacy. It’s the long term SAD efficacy. That is still in play and fast tracked by the FDA.
News 
Market Data 
Discover 
